Pure Ocular Myasthenia gravis
Neurology International Open · 01.01.2018 · 02 (01) · E51-E55
DOI: 10.1055/s-0043-122245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurology International Open, erschienen am 01.01.2018. Verfasst von Lukas Kirzinger und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Pure ocular myasthenia was always described as a separate entity in historical publications. More than 50% of patients develop generalized symptoms in the course of the disease. Therefore pure ocular symptoms can be the beginning of generalized myasthenia, nevertheless there is a small group of patients who suffer lifelong purely ocular symptoms. The basis, therefore, seems to be special immunological, biochemical and pathophysiological mechanisms leading to specific local changes of the neuromuscular junction. The diagnostic procedure is hampered as antibodies against acethylcholine receptors and MuSK can be demonstrated in less than 50% of these patients. Therapy of pure ocular myasthenia does not differ fundamentally from other subgroups of myasthenia gravis and is implemented with cholinesterase inhibitors, steroids and common immunosuppressants. Thymomectomy is not recommended in general, but randomized controlled studies are lacking.
Zitieren
APA
Kirzinger, L., Schötz, S., & Schalke, B. (2018). Pure Ocular Myasthenia gravis. Neurology International Open, 02(01), E51-E55. https://doi.org/10.1055/s-0043-122245
Vancouver
Kirzinger L, Schötz S, Schalke B. Pure Ocular Myasthenia gravis. Neurology International Open. 2018;02(01):E51-E55. doi:10.1055/s-0043-122245
BibTeX
@article{Kirzinger2018,
author = {Kirzinger, Lukas and Schötz, Sophie and Schalke, Berthold},
title = {Pure Ocular Myasthenia gravis},
journal = {Neurology International Open},
year = {2018},
volume = {02},
number = {01},
pages = {E51--E55},
doi = {10.1055/s-0043-122245}
}
EUVIMED